Effects of Darbepoetin Alfa Administered Every Two Weeks on Hemoglobin and Quality of Life of Patients Receiving Chemotherapy

Jody Folloder

ONF 2005, 32(1), 81-91. DOI: 10.1188/05.ONF.81-91

Purpose/Objectives: To review the effects on hemoglobin and quality of life of an every-two-week (Q2W) regimen of the erythropoietic agent darbepoetin alfa for treating patients with chemotherapy-induced anemia.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.